Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Andrew P. A. Crew
Observed names:
A P Crew,
A P. Crew,
A. Crew,
A. P. A. CREW,
A.P. Crew,
A.P.A. Crew,
Andrew Crew,
Andrew P Crew,
Andrew P. Crew,
Andrew P.A. Crew,
Andrew P. Crew,
Crew, A.P.
show all 12
Observed institutions:
Nationwide Children's Hospital,
University of Liverpool,
Queen's University,
Proteus (United Kingdom),
Arvinas (United States),
Keymed Biosciences Inc. (China)
show all 6
OpenAlex ID:
A5007702221
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
2015
·
Jing Lu
, Yimin Qian
, et al.
·
Chemistry & Biology
·
1,153
PDF
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
2016
·
Kanak Raina
, Jing Lu
, et al.
·
Proceedings of the National Academy of Sciences
·
858
PDF
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study
2017
·
George M. Burslem
, Blake E. Smith
, et al.
·
Cell chemical biology
·
692
PDF
Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance
2018
·
Jemilat Salami
, Shanique Alabi
, et al.
·
Communications Biology
·
354
PDF
Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1
2017
·
Andrew P. Crew
, Kanak Raina
, et al.
·
Journal of Medicinal Chemistry
·
256
ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.
2019
·
Taavi Neklesa
, Lawrence B Snyder
, et al.
·
Journal of Clinical Oncology
·
222
Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin
2011
·
Shripad V. Bhagwat
, Prafulla C. Gokhale
, et al.
·
Molecular Cancer Therapeutics
·
203
Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells
2017
·
D T Saenz
, W Fiskus
, et al.
·
Leukemia
·
187
BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells
2017
·
B Sun
, W Fiskus
, et al.
·
Leukemia
·
185
Abstract 44: The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer
2021
·
Lawrence B. Snyder
, John J. Flanagan
, et al.
·
Cancer Research
·
128
A highly effective one-pot synthesis of quinolines from o-nitroarylcarbaldehydes
2006
·
An-Hu Li
, Eilaf Ahmed
, et al.
·
Organic & Biomolecular Chemistry
·
89
OSI-930: A Novel Selective Inhibitor of Kit and Kinase Insert Domain Receptor Tyrosine Kinases with Antitumor Activity in Mouse Xenograft Models
2006
·
Andrew J. Garton
, Andrew P.A. Crew
, et al.
·
Cancer Research
·
85
PDF
Palladium-Catalyzed Direct Heck Arylation of Dual π-Deficient/π-Excessive Heteroaromatics. Synthesis of C-5 Arylated Imidazo[1,5-a]pyrazines
2008
·
Jian-Xin Wang
, J. Adam McCubbin
, et al.
·
Organic Letters
·
83
Abstract 43: Discovery of ARV-110, a first in class androgen receptor degrading PROTAC for the treatment of men with metastatic castration resistant prostate cancer
2021
·
Lawrence B. Snyder
, Taavi K. Neklesa
, et al.
·
Cancer Research
·
78
Abstract 5236: ARV-110: An androgen receptor PROTAC degrader for prostate cancer
2018
·
Taavi Neklesa
, Lawrence B. Snyder
, et al.
·
Cancer Research
·
65
The generation of 2,3-dihydro-2,3-bis-(methylene)thiophenes from 4,6-dihydrothieno[3,4-b]thiophene 5,5-dioxides
1990
·
A.P.A. Crew
, G. Jenkins
, et al.
·
Tetrahedron Letters
·
50
Heterocyclic fused 2,5-dihydrothiophene S,S-dioxides as precursors to heterocyclic o-quinodimethanes
1992
·
Lynne M. Chaloner
, Andrew P.A. Crew
, et al.
·
Tetrahedron
·
49
Heterocyclic o-xylylenes: Thiazole, oxazole and imidazole analogues
1990
·
P.M.S. Chauhan
, A.P.A. Crew
, et al.
·
Tetrahedron Letters
·
41
One-Pot Friedländer Quinoline Synthesis: Scope and Limitations
2010
·
An-Hu Li
, David Beard
, et al.
·
Synthesis
·
40
Novel inhibitors of mTORC1 and mTORC2.
2010
·
Shripad V Bhagwat
, Andrew P Crew
·
PubMed
·
36
1,3-Disubstituted-imidazo[1,5-a]pyrazines as insulin-like growth-factor-I receptor (IGF-IR) inhibitors
2006
·
Mark J. Mulvihill
, Qun-Sheng Ji
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
35
An oral androgen receptor PROTAC degrader for prostate cancer.
2017
·
Taavi K Neklesa
, Lawrence B Snyder
, et al.
·
Journal of Clinical Oncology
·
29
Discovery of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1: Optimization of kinase selectivity and pharmacokinetics
2013
·
Keith R. Hornberger
, Xin Chen
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
28
Abstract ND03: Discovery of ARV-766, an androgen receptor degrading PROTAC® for the treatment of men with metastatic castration resistant prostate cancer
2023
·
Larry Snyder
, S H. Lee
, et al.
·
Cancer Research
·
27
Imidazo[1,5-a]pyrazines: Orally efficacious inhibitors of mTORC1 and mTORC2
2011
·
Andrew P. Crew
, Shripad V. Bhagwat
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
24
Show more works
View as search
Works count:
74
Citation count:
5,183
H-index:
24
I10-index:
33
Year
Topic
Type
